Targeted drug Selpercatinib has received accelerated approval from the FDA. It is cancer-independent and may benefit any solid tumour with a positive RET gene fusion. It is up to 84% effective in selected patients with non-small cell lung cancer!
A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.
Everyone wants to be in good health because we all know that good health is the only way to live a better life. However, many diseases still occur frequently nowadays, so we need to know about the common diseases
DZD1516 is a reversible, selective HER2-targeting agent with full blood-brain barrier penetration. It has demonstrated good therapeutic response in phase I studies in patients with metastatic HER2-positive breast cancer, including breast cancer patients with central nervous system metastases.
Pancreatic cancer is a very complex and common tumour of the pancreas, and the malignancy of this disease is relatively high.
The Moffitt Cancer Center & Research Institute is a non-profit cancer treatment and research centre established in 1981 by the Florida Legislature and opened on the campus of the University of South Florida in October 1986.
The results of a new study show that Ubamatamab, a bispecific antibody drug, has shown excellent results and a good safety profile in patients with ovarian cancer.
For many patients after early lung cancer surgery, it is common for them to worry about recurrence. For this reason, many patients tend to undergo CT examinations more closely to ensure that they have not had a recurrence. However, a recent new study conducted by researchers from Washington University School of Medicine in St. Louis found that even with more frequent CT reviews, post-operative outcomes for lung cancer did not improve...
On November 4, 2022, the U.S. FDA has approved the marketing of mivituximab soratansine (Elahere), a cutting-edge antibody-coupled drug targeting folate receptor alpha (FRα), for the treatment of adult patients with epithelial ovarian, fallopian tube or primary peritoneal cancer who have received one to three systemic treatment regimens and are folate receptor alpha (FRα)-positive and platinum-resistant.
MD Anderson Cancer Center, founded in 1941, is a world-renowned oncology hospital located in Houston, Texas, USA, and was one of the three early comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971. It is one of the first three comprehensive cancer treatment centres designated by the National Cancer Initiative in 1971, and one of 39 comprehensive cancer treatment centres designated by the Medical Oncology Society, and is recognised as a good cancer hospital.
